Option chain shows key data for Hexagon Purus's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hexagon Purus.

Hexagon Purus (OTC:HPURF) Stock, Option Chain

Hexagon Purus ASA is a provider of Hydrogen Type 4 high-pressure cylinders, complete vehicle systems, and battery packs for fuel cell electric and battery electric vehicles including hybrid mobility applications on light, medium, and heavy-duty vehicles, buses, marine, rail, and aerospace. The company has a geographic presence in Norway, Europe, North America, and Others.

News

Penny Stocks

Small Cap

Global

Markets

Tech

Trading Ideas

HINOF

HPURF

NKLA

PCRFF

PTRAQ

TSLA

TUSIMPLE HOLDINGS INC A by TuSimple Holdings Inc.

TSPH

LAS VEGAS — The Advanced Clean Truck Expo is a come-all event. Until this year, Tesla has passed on attending.

The ACT Expo has outgrown the art deco charm of Long Beach and the &#34;Disney-fied&#34; atmosphere of Anaheim, California. This year, it moved to convention mecca with exhibitors filling the North Hall of the sprawling Las Vegas Convention Center.

Tesla to Trucking Industry: Step Up Your Electric Game

BLDP

Hexagon Purus, Ballard Partner To Launch Class 6 &amp; 7 Fuel Cell Electric Trucks

Hexagon Purus ASA

With <a href="https://www.benzinga.com/topic/interest-rates">ultra-low interest rates</a> firmly in the rearview mirror, Jeff Weniger, Head of Equity Strategy at WisdomTree, has a clear message for investors: &#8220;Anything in the high-4s on a 10-year Treasury rate puts the S&amp;P 500's earnings yield at a level where it either barely exceeds or does not exceed the risk-free yield.&#8221;
In other words, it&#8217;s time to rethink the Growth vs. Value debate.
In an exclusive interview with Benzinga, Weniger said that investors in the "higher for longer" camp should focus on Value stocks. ETFs such as the Vanguard Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>), the SPDR Select Sector Fund &#8211; Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), the Vanguard Small-Cap Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VBR#NYSE">VBR</a>) and the iShares Select Dividend ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVY#NASDAQ">DVY</a>) provide exposure to value equity in the U.S.
Read Also: <a href="https://www.benzinga.com/25/01/43059744/exclusive-can-sp-500-repeat-large-gains-from-donald-trumps-first-term-a-second-time-around-readers-say-this-return-range-most-likely" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Can S&amp;P 500 Repeat Large Gains From Donald Trump&#8217;s First Term A Second Time Around? Readers Say This Return Range Most Likely</a>
As rates rise, the yields on Treasury bonds become more competitive with stock market earnings, making growth stocks, which have long outperformed, much less attractive. In such a scenario, investors in growth-focused ETFs such as the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) and the Vanguard Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VUG#NYSE">VUG</a>) should remain wary of their holdings.
"In that scenario, which is a live one, investors need to reassess the more speculative portions of their portfolio," he said.
<h2 class="wp-block-heading">Tariff Tension &amp; Its Surprising Impact</h2>
While tariffs continue to be a topic of concern, Weniger suggests that much of this risk is already baked into the market. &#8220;Tariff risk is one of the most priced-in risks we have seen for some time,&#8221; he explained.
Reshoring efforts, which began during the pandemic, are unlikely to be significantly affected by new tariffs. So, if you&#8217;re expecting a major tariff shock to upend the market, Weniger believes the impact may be much smaller than anticipated.
<h2 class="wp-block-heading">Inflation's Hidden Risks: Housing Edition</h2>
Beyond energy prices, Weniger identifies a potentially overlooked inflation risk: housing. &#8220;The market needs to contend with the very real arithmetic of Owners Equivalent Rent in the CPI calculation,&#8221; he said.
Even if home prices stagnate or fall, the inflated housing costs will continue to push the CPI higher.
<h2 class="wp-block-heading">Navigating Market Sentiment</h2>
With macro uncertainties looming, Weniger advises investors to manage their risk carefully. &#8220;Sentiment is arguably bubbly in certain pockets of U.S. markets and downright moribund in others,&#8221; he adds, suggesting that international stocks might be a safer bet while scaling back exposure to U.S. equities in the current volatile climate.
The Vanguard FTSE Developed Markets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEA#NYSE">VEA</a>), the iShares Core MSCI EAFE ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEFA#BATS">IEFA</a>) and the WisdomTree International Hedged Quality Dividend Growth Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHDG#NYSE">IHDG</a>) provide exposure to international equity.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43083803/market-bets-on-trumps-tariff-announcement-plummet-dollar-falls-whats-going-on">Market Bets On Trump&#8217;s Tariff Announcement Plummet, Dollar Falls: What&#8217;s Going On?</a></li>
</ul>
Image created using artificial intelligenc via Midjourney.

Government

Long Ideas

Regulations

Broad U.S. Equity ETFs

Exclusives

Interview

ETFs

iShares Dow Jones Select Dividend Index Fund

IEFA

IHDG

EXCLUSIVE: 'Higher For Longer' Interest Rates Shift Investors To Value, Tariff Fears Overstated, Says WisdomTree Expert

Whales with a lot of money to spend have taken a noticeably bullish stance on Union Pacific.
Looking at options history for Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 75% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $145,148 and 9, calls, for a total amount of $367,296.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $255.0 for Union Pacific during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Union Pacific options trades today is 683.27 with a total volume of 1,439.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Union Pacific's big money trades within a strike price range of $130.0 to $255.0 over the last 30 days.
<h3>Union Pacific 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737578730_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.9</td>
<td>$8.4</td>
<td>$8.45</td>
<td>$210.00</td>
<td>$84.4K</td>
<td align="right">893</td>
<td align="right">104</td>
</tr>
<tr>
<td>UNP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.97</td>
<td>$250.00</td>
<td>$59.9K</td>
<td align="right">19</td>
<td align="right">410</td>
</tr>
<tr>
<td>UNP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.4</td>
<td>$5.1</td>
<td>$5.4</td>
<td>$255.00</td>
<td>$57.1K</td>
<td align="right">223</td>
<td align="right">108</td>
</tr>
<tr>
<td>UNP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$106.5</td>
<td>$105.4</td>
<td>$106.5</td>
<td>$130.00</td>
<td>$53.2K</td>
<td align="right">0</td>
<td align="right">5</td>
</tr>
<tr>
<td>UNP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$8.6</td>
<td>$8.4</td>
<td>$8.48</td>
<td>$230.00</td>
<td>$43.2K</td>
<td align="right">83</td>
<td align="right">179</td>
</tr>
</tbody>
</table>

<h3>About Union Pacific</h3>
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the us, Union Pacific generated $24 billion of revenue in 2023 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
After a thorough review of the options trading surrounding Union Pacific, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Union Pacific</h3>
<ul>
<li>With a trading volume of 1,819,700, the price of UNP is down by 0.0%, reaching $236.74.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 1 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Union Pacific</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $261.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Union Pacific, targeting a price of $265. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Union Pacific, which currently sits at a price target of $265. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Union Pacific with a target price of $253. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Union Pacific options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Union Pacific's Options Frenzy: What You Need to Know

High-rolling investors have positioned themselves bearish on Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in RCL often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 15 options trades for Royal Caribbean Gr. This is not a typical pattern.
The sentiment among these major traders is split, with 13% bullish and 53% bearish. Among all the options we identified, there was one put, amounting to $31,328, and 14 calls, totaling $593,319.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $210.0 and $247.5 for Royal Caribbean Gr, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Royal Caribbean Gr's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Royal Caribbean Gr's whale activity within a strike price range from $210.0 to $247.5 in the last 30 days. 
<h3>Royal Caribbean Gr Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737578725_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$14.3</td>
<td>$14.25</td>
<td>$14.3</td>
<td>$240.00</td>
<td>$95.8K</td>
<td align="right">593</td>
<td align="right">70</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$14.6</td>
<td>$14.15</td>
<td>$14.4</td>
<td>$240.00</td>
<td>$57.6K</td>
<td align="right">593</td>
<td align="right">122</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/31/25</td>
<td>$9.45</td>
<td>$8.8</td>
<td>$9.01</td>
<td>$237.50</td>
<td>$54.0K</td>
<td align="right">8</td>
<td align="right">65</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/24/25</td>
<td>$9.15</td>
<td>$8.1</td>
<td>$8.55</td>
<td>$230.00</td>
<td>$51.2K</td>
<td align="right">124</td>
<td align="right">64</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$13.65</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$225.00</td>
<td>$39.6K</td>
<td align="right">76</td>
<td align="right">35</td>
</tr>
</tbody>
</table>

<h3>About Royal Caribbean Gr</h3>
Royal Caribbean is the world's second-largest cruise company, operating 68 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021.
<h3>Present Market Standing of Royal Caribbean Gr</h3>
<ul>
<li>Currently trading with a volume of 1,320,557, the RCL's price is down by -0.69%, now at $241.61. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What The Experts Say On Royal Caribbean Gr</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $252.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Royal Caribbean Gr, maintaining a target price of $210. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Royal Caribbean Gr, maintaining a target price of $295. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Royal Caribbean Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on RCL Options

Deep-pocketed investors have adopted a bearish approach towards Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BKNG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 74 extraordinary options activities for Booking Holdings. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 28% leaning bullish and 40% bearish. Among these notable options, 43 are puts, totaling $3,166,786, and 31 are calls, amounting to $18,026,032.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3300.0 and $7900.0 for Booking Holdings, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Booking Holdings options trades today is 31.12 with a total volume of 446.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Booking Holdings's big money trades within a strike price range of $3300.0 to $7900.0 over the last 30 days.
<h3>Booking Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737578719_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$53.4</td>
<td>$53.3</td>
<td>$53.39</td>
<td>$4500.00</td>
<td>$197.5K</td>
<td align="right">1</td>
<td align="right">39</td>
</tr>
<tr>
<td>BKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$372.0</td>
<td>$360.1</td>
<td>$372.0</td>
<td>$5000.00</td>
<td>$186.0K</td>
<td align="right">6</td>
<td align="right">6</td>
</tr>
<tr>
<td>BKNG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$415.4</td>
<td>$408.8</td>
<td>$415.4</td>
<td>$4850.00</td>
<td>$166.1K</td>
<td align="right">42</td>
<td align="right">2</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$813.2</td>
<td>$793.4</td>
<td>$803.2</td>
<td>$4000.00</td>
<td>$160.6K</td>
<td align="right">4</td>
<td align="right">2</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$98.0</td>
<td>$90.1</td>
<td>$98.0</td>
<td>$5000.00</td>
<td>$117.6K</td>
<td align="right">69</td>
<td align="right">11</td>
</tr>
</tbody>
</table>

<h3>About Booking Holdings</h3>
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
In light of the recent options history for Booking Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Booking Holdings's Current Market Status</h3>
<ul>
<li>With a trading volume of 244,973, the price of BKNG is down by -1.93%, reaching $4595.91.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Booking Holdings</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $4990.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Booking Holdings, which currently sits at a price target of $4470. 
&#x2A; An analyst from Wedbush has decided to maintain their Outperform rating on Booking Holdings, which currently sits at a price target of $5500. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Booking Holdings with a target price of $5000. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Booking Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

BKNG

Unpacking the Latest Options Trading Trends in Booking Holdings

Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) has outperformed the market over the past 5 years by 27.8% on an annualized basis producing an average annual return of 40.98%. Currently, Targa Resources has a market capitalization of $46.46 billion. 
Buying $100 In TRGP: If an investor had bought $100 of TRGP stock 5 years ago, it would be worth $567.40 today based on a price of $213.06 for TRGP at the time of writing.
<h3>Targa Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737578709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TRGP

Here's How Much You Would Have Made Owning Targa Resources Stock In The Last 5 Years

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Analyst Color

Biotech

Health Care

Price Target

Initiation

Analyst Ratings

Movers

General

AMGN

CYTK

RPRX

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

WIIM

LRCX

Lam Research shares are trading higher amid strength in chip stocks.

MSTR

MicroStrategy shares are trading lower. Weakness may be due to a drop in Bitcoin.

GE Vernova shares are trading higher despite worse-than-expected Q4 EPS and revenue. The stock initially fell after the report but has since reversed.

Schlumberger shares are trading lower amid weakness in energy stocks.

The first U.S. based exchange-traded fund turns 32 years old today and is one of the most<a href="https://www.benzinga.com/etfs"> popular ETFs today.</a>
Here's a look at the history of the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and how much an investment at launch would be worth today. What Happened: Launched with seed funding of $6.5 million, the SPDR S&amp;P 500 ETF Trust<a href="https://www.benzinga.com/news/23/01/30529288/worlds-first-etf-turns-30-heres-how-much-money-youd-have-if-you-invested-1-000-when-it-launched" target="_blank" rel="noreferrer noopener"> became the first U.S. ETF </a>on Jan. 22, 1993.
The ETF was approved by the U.S. Securities and Exchange Commission several years after&nbsp;State Street Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>)&nbsp;applied for the fund.
Initial interest in the ETF was poor and the fund was almost closed before investors came around to the idea of using ETFs as investment vehicles.
The success of the SPY ETF led to other financial institutions launching similar ETFs that track the S&amp;P 500 Index, one of the largest and most well-known stock market indexes.
The&nbsp;iShares Core S&amp;P 500 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>)&nbsp;and&nbsp;Vanguard S&amp;P 500 Index Fund ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>)&nbsp;launched in 2000 and 2010, respectively.
Today, the three ETFs that track the S&amp;P 500 are the largest in the world according to&nbsp;<a href="https://etfdb.com/compare/market-cap/" target="_blank" rel="noreferrer noopener">ETFDB&nbsp;</a>with the following assets under management:
<ul>
<li>SPY:&nbsp;$623.5 million</li>
<li>VOO: $603.1 million</li>
<li>IVV: $594.2 million</li>
</ul>
After posting its worst one-year performance in more than a decade for the 2022 year, the S&amp;P 500 Index, which features 500 leading U.S. publicly traded companies, with a primary emphasis on market capitalization, saw outperformance in 2023, ending the year up over 20% and riding a streak of winning weeks. The ETF followed up the rebound with a 24.9% gain in 2024.
In 2024, the S&amp;P 500 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678368/sp-500-hits-57-all-time-highs-in-record-breaking-2024-magnificent-7-drive-30-of-nasdaqs-surge">reached new all-time highs </a>on numerous occasions, boosted by soaring valuations for technology stocks.
Here are the current top&nbsp;<a href="https://www.ssga.com/us/en/institutional/etfs/funds/spdr-sp-500-etf-trust-spy" target="_blank" rel="noreferrer noopener">holdings&nbsp;</a>of the SPDR S&amp;P 500 ETF at the time of writing:
<ol>
<li>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): 6.7%</li>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): 6.6%</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): 6.2%</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): 4.2%</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): 2.6%</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 2.3%</li>
<li>Alphabet Inc Class A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): 2.3%</li>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): 2.2%</li>
<li>Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>): 1.9%</li>
<li>Berkshire Hathaway Class B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>): 1.7%</li>
</ol>
Read Also: <a href="https://www.benzinga.com/25/01/43059744/exclusive-can-sp-500-repeat-large-gains-from-donald-trumps-first-term-a-second-time-around-readers-say-this-return-range-most-likely">EXCLUSIVE: Can S&amp;P 500 Repeat Large Gains From Donald Trump&#8217;s First Term A Second Time Around? Readers Say This Return Range Most Likely</a>
Investing $1,000 in SPY Stock:&nbsp;While the idea of ETFs was new at the time, investors who followed State Street into the idea of a new investment vehicle to track the S&amp;P 500 would have been pleasantly rewarded.
The SPDR S&amp;P 500 ETF traded at around $43.61 in its first days of trading. A $1,000 investment could have purchased 22.93 shares at the time.
The $1,000 investment would be worth $13,930.20 today based on a price of $607.51 for the SPY at the time of writing. This represents a hypothetical return of $1,293.0% over the past 32 years.
Investors who bought the SPY on Jan. 22, 1993, based on a price of $25.02 adjusted for dividends would have an even larger return. The SPY has an adjusted price of $25.02 when adjusted for dividends, which means a $1,000 investment could have purchased 39.97 shares.
The $1,000 investment would be worth $24,282.17 today. This represents a hypothetical return of 2,328.2% over the past 32 years.
Read Next: 
<ul>
<li><a href="http://= https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43041374/exclusive-how-high-will-sp-500-go-under-donald-trump-in-2025-readers-are-optimistic-26-say-this">EXCLUSIVE: How High Will S&amp;P 500 Go Under Donald Trump In 2025? Readers Are Optimistic, 26% Say This…</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Image: Shutterstock

Education

AAPL

AMZN

AVGO

GOOG

GOOGL

MSFT

NVDA

Happy Birthday S&P 500 SPY ETF! If You Invested $1,000 In SPY At Launch, Here's How Much You'd Have Today

NOV's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) short percent of float has risen 21.04% since its last report. The company recently reported that it has 20.68 million shares sold short, which is 5.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>NOV Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737577822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for NOV has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing NOV's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, NOV's peer group average for short interest as a percentage of float is 8.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into NOV's Recent Short Interest

Helius Medical Tech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NYSE">HSDT</a>) short percent of float has risen 44.44% since its last report. The company recently reported that it has 230 thousand shares sold short, which is 6.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Helius Medical Tech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737577817_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Helius Medical Tech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Helius Medical Tech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Helius Medical Tech's peer group average for short interest as a percentage of float is 5.55%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HSDT

How Is The Market Feeling About Helius Medical Tech?

EMCOR Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) short percent of float has risen 13.01% since its last report. The company recently reported that it has 490 thousand shares sold short, which is 1.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>EMCOR Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737577812_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for EMCOR Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing EMCOR Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, EMCOR Group's peer group average for short interest as a percentage of float is 4.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into EMCOR Group's Recent Short Interest

Savings account balances are one of those topics that rarely come up in conversation. People might talk about how much they spent on their last vacation or complain about the rising cost of groceries, but ask someone how much they have saved and you'll probably get an awkward silence.
It's no surprise – money is personal and savings can feel like a <a href="https://www.benzinga.com/24/11/42173927/how-rich-are-you-find-out-whether-you-rank-as-upper-middle-or-lower-class-based-on-income-and-other-factors">measure of success</a> (or stress). Even close family members or friends tend to keep that number to themselves. But you&#8217;re not alone if you've ever wondered how your balance compares to others.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/are-you-rich-2">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
The Federal Reserve's 2022 Survey of Consumer Finances revealed that the average American household has $62,410 stashed in transaction accounts, including savings, checking, money market and call deposit accounts. Sounds like a lot, right? But averages are sneaky. They're easily skewed by a few outliers, i.e: the ultra-wealthy. If Jeff Bezos walked into your local coffee shop, the "average" customer's net worth would shoot through the roof, even though most are just there <a href="https://www.benzinga.com/personal-finance/24/06/39360372/kevin-oleary-urges-stop-wasting-money-on-5-50-coffee-ramit-sethi-calls-him-out-its-not-the-f-g-c">ordering $5.50 lattes</a>.
That's why the median savings balance – the middle number when all balances are lined up – is much more relatable. For 2022, it was $8,000. In other words, half of American households have less than $8,000 saved. That's a far cry from $62K and feels, well, a little more realistic for most people.
See Also: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
Breaking It Down: Age, Income and Lifestyle
Savings balances vary wildly depending on age, income and whether or not you're splitting expenses with a partner.&nbsp;
<h2 class="wp-block-heading">By Age</h2>
Unsurprisingly, the older you are, the more savings you'll likely have – thanks to years of work, investments and, for some, a lifetime of frugality. Here's how it shakes out:
• Under 35: Average $20,540 &#x7C; Median $5,400
• 35-44: Average $41,540 &#x7C; Median $7,500
• 45-54: Average $71,130 &#x7C; Median $8,700
• 55-64: Average $72,520 &#x7C; Median $8,000
• 65-74: Average $100,250 &#x7C; Median $13,400
• 75+: Average $82,800 &#x7C; Median $10,000
While averages rise steadily, medians don't jump as much – another reminder that outliers can distort the big picture.
<h2 class="wp-block-heading">By Income</h2>
<a href="https://www.benzinga.com/personal-finance/24/09/41102547/is-your-income-higher-than-the-average-middle-class-household-heres-what-theyre-earning">Income plays an even bigger role</a>. It's easier to save more when you're earning more, but for those in lower brackets, the numbers are sobering:
• $0-$34,599: Median $900
• $35,600-$59,499: Median $2,550
• $59,500-$91,899: Median $7,400
• $91,900-$153,099: Median $15,760
• $153,100-$245,399: Median $33,800
• $245,400+: Median $111,600
These figures highlight why experts often recommend saving a percentage of your income rather than comparing dollar amounts with others.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
By Household Type
Family dynamics matter, too. Couples without children tend to top the savings charts, likely because they're spending less on diapers, tuition and braces. Here's how the averages stack up:
• Single, no kids (under 55): Average $19,320
• Single with kids: Average $16,800
• Couple, no kids: Average $103,140
• Couple with kids: Average $73,890
Where Do You Stand?
So, how do your savings compare? Start by looking at the median figure: $8,000. Are you above or below that line? Then, dig into your age group, income bracket and household setup.
But remember, it's not just about how you compare to others – it's about how your savings align with your goals. Financial advisors typically suggest saving 3-6 months of living expenses for emergencies, but the real target depends on your circumstances.
Trending: The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">Here's how to know if your nest egg is keeping pace.</a>
What If You're Not There Yet?
If your balance isn't quite where you'd like it to be, don't panic. There are plenty of ways to build up your savings:
1. Set a budget. Knowing where your money goes is the first step.
2. Trim expenses. Cut back on nonessentials (like subscriptions you forgot you had).
3. Shop for better interest rates. As of January 2025, the average savings account offers a mere 0.55% APY, but online banks often offer much higher rates.
The key is to focus on progress, not perfection. Whether starting with $900 or $90,000, every dollar saved is a step closer to financial security.&nbsp;
So, next time someone asks if your savings are above average, you can smile and say, "Define average." And if you're unsure about your savings goals, consider <a href="https://www.benzinga.com/money/are-you-rich">consulting a financial advisor</a>. They can help you create a plan that fits your unique circumstances and keeps you moving toward your desired future.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

Is Your Savings Account Balance Above Average? Here's A Look At The Surprisingly High Amount Of Cash Households Are Stashing Away

Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) has outperformed the market over the past 10 years by 12.93% on an annualized basis producing an average annual return of 24.52%. Currently, Palo Alto Networks has a market capitalization of $123.54 billion. 
Buying $100 In PANW: If an investor had bought $100 of PANW stock 10 years ago, it would be worth $889.91 today based on a price of $188.26 for PANW at the time of writing.
<h3>Palo Alto Networks's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737577810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PANW

Here's How Much $100 Invested In Palo Alto Networks 10 Years Ago Would Be Worth Today

American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) is set to report its fourth-quarter financial results on Thursday before the opening bell. Here's a look at what to look <a href="https://www.benzinga.com/quote/aal#:~:text=American%20Airlines%20Charts,for%20Q4%20earnings.">for in the report. </a>
What To Watch: After posting a $149 million net loss in the third quarter, investors will be keen to see if American Airlines has returned to profitability. The company&#8217;s updated guidance suggests improved financial performance compared to earlier expectations.&nbsp;
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43136971/will-soundhound-ai-stock-get-a-boost-from-project-stargate">Will SoundHound AI Stock Get A Boost From Project Stargate?&nbsp;</a>
American Airlines raised its Q4 outlook in December and now expects earnings in the range of 55 cents to 75 cents per share, versus its prior guidance of 25 cents to 50 cents.
According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect the company to report earnings of 64 cents per share and quarterly revenue of $13.4 billion.&nbsp;
Investors will also be interested in American Airlines&#8217; operational metrics, including passenger load factors, capacity and fuel costs, which can significantly impact profitability.
The company reported a passenger load factor of 86.6% and average aircraft fuel price of $2.50, including related taxes (dollars per gallon) in the<a href="https://www.benzinga.com/news/earnings/24/10/41518666/american-airlines-q3-earnings-revenue-and-profit-beat-annual-outlook-hike-debt-reduction-more"> third quarter</a>.&nbsp;
Last week, B of A Securities analyst Andrew Didora upgraded American Airlines stock from Underperform to Neutral and raised the<a href="https://www.benzinga.com/quote/AAL/analyst-ratings"> price target </a>from $12 to $20 heading into its fourth-quarter earnings release.&nbsp;
AAL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, American Airlines shares are down 0.59% at $18.53 at the time of publication Wednesday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43130930/trump-looking-at-10-tariff-on-china-starting-feb-1">Trump &#8216;Looking At&#8217; 10% Tariff On China Starting Feb. 1 </a></li>
</ul>
Image: Shutterstock

Earnings

Previews

Travel

American Airlines Reports Q4 Thursday: What To Watch

The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Genzyme Corporation regarding significant violations at <a href="https://www.benzinga.com/topic/fda-0">its Framingham, Massachusetts, facility</a>.
After an inspection conducted between June 12 and July 9, 2024 the agency flagged major concerns about the facility&#8217;s processes for producing active pharmaceutical ingredients, or APIs.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a>
<h3 class="wp-block-heading">Inspection Findings</h3>
<ul>
<li>FDA investigators documented several critical issues, including a failure to adequately investigate deviations, address manufacturing inconsistencies, and use properly designed equipment.</li>
<li>Approximately 20% of bioreactor runs between January 2022 and July 2024 were rejected due to contamination or other quality failures, highlighting serious process control deficiencies.</li>
<li>Investigations into these incidents often lacked thorough root cause analyses, appropriate corrective actions, or adequate documentation.</li>
<li>For example, two lots of APIs were found to contain visible particles, but investigations failed to address all contributing factors. Additionally, high-pressure product leakage events during manufacturing were inadequately reviewed, and engineering study conclusions were ignored.</li>
<li>The FDA <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanofi-690604-01152025" target="_blank" rel="noreferrer noopener">noted</a> instances where Genzyme deviated from validated manufacturing processes, increasing the risk of microbial contamination.</li>
<li>One notable deviation involved the unauthorized substitution of manufacturing components, which was later linked to contamination events.</li>
<li>The agency also criticized using unsuitable equipment, including mobile carts and devices with known design flaws that could allow microbial ingress.</li>
</ul>
The facility&#8217;s quality unit was also scrutinized for its inability to ensure compliance with current Good Manufacturing Practices standards. As of June 2024, the quality unit had 84 open and overdue deviation investigations, some exceeding 180 days. FDA inspectors observed unreported deviations, such as improper aseptic practices and equipment setup issues.
The FDA also found Genzyme&#8217;s proposed corrective and preventive actions (CAPAs) insufficient.
Sanofi must respond within 15 working days, outlining its corrective measures and provide the FDA with a timeline for completion.
Price Action: Sanofi stock is down 0.91% at $51.22 at last check Wednesay. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43128325/ge-vernova-mixed-q4-revenue-misses-but-orders-surge-22-amid-strong-electrification-demand" target="_blank" rel="noreferrer noopener">GE Vernova Mixed Q4: Revenue Misses, But Orders Surge 22% Amid Strong Electrification Demand</a></li>
</ul>
Image: Shutterstock

Large Cap

Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses

Canaccord Genuity initiated coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a medical device company focused on the development, manufacture and commercialization of technology for the surgical treatment of spinal and broader orthopedic disorders.
Canaccord Genuity analyst Caitlin Cronin writes that over two years have passed since Orthofix merged with SeaSpine. With a new management team in place since early 2024, the company has successfully integrated the two teams and portfolios.
It is now ready to move forward with its long-term plan and unified strategy. The analyst is optimistic about Orthofix Medical&#8217;s unique offerings and plans for ongoing innovation, using its entire portfolio to drive growth across its various segments.
This cohesion is helping Orthofix Medical not only aim for above-market growth but also focus on cash generation and improve profit margins.
Canaccord Genuity has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/OFIX/analyst-ratings" rel="noreferrer noopener">price forecast of $24</a>.
The analyst Cronin adds that both 7D and ortho sub-segments are in Orthofix Medical&#8217;s highest growing markets, with the company estimating market growth of 10-12% in enabling tech and 5-6% in its ortho segment.
Overall, the company is targeting profitable growth. Additionally, Orthofix Medical&#8217;s current valuation appears attractive, trading well below the average of its small-cap and spine industry peers.
Third quarter 2024 net sales increased 7% year-over-year to $196.6 million, with 18% growth in U.S. Spine Fixation net sales driven by distribution expansion and further penetration in existing accounts, 9% growth in Bone Growth Therapies net sales and <a href="https://www.benzinga.com/pressreleases/24/11/b41802749/orthofix-reports-third-quarter-2024-results-reiterates-full-year-2024-financial-guidance-and-intro" target="_blank" rel="noreferrer noopener">13% growth in BGT Fracture net sales</a>.
The company expects 2024 sales of $795 million-$800 million compared to the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $796.6 million</a>.
The company sees adjusted EBITDA guidance of $64 million to $69 million and expects positive free cash flow for the second half of 2024.
Price Action: OFIX stock is down 0.05% at $18.35 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43136830/lockheed-martin-secures-270-million-us-air-force-deal" target="_blank" rel="noreferrer noopener">Lockheed Martin Secures $270 Million US Air Force Deal For Next-Gen F-22 Infrared Defense</a></li>
</ul>
Image: Shutterstock

OFIX

This Analyst Says Orthopedic-Focused Orthofix Medical Is Positioned For Growth

Cryptocurrency markets are trading lower on Wednesday as investors await Donald Trump's executive orders on crypto and his <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43135463/strategic-bitcoin-reserve-probability-up-to-64-despite-trump-silence-on-crypto">announcement regarding a strategic Bitcoin reserve</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$104,661.95</td>
<td>-2.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,266.86&nbsp;</td>
<td>-2%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$266.11</td>
<td>+5.4%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$3.24</td>
<td>+1.4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3614</td>
<td>-5.9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002042</td>
<td>-2.8%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 9.6% and daily active addresses up by 1.95%. Transactions greater than $100,000 are down from 16,250 to 13,808 in a single day. Exchanges netflows are down by 307.6%.</li>
<li>Coinglass data reports 88,536 traders were liquidated in the past 24 hours for $161.09 million.</li>
<li>Arkham Intelligence data shows Blackrock purchased $600 million of BTC, marking its third largest purchase this year.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43135463/strategic-bitcoin-reserve-probability-up-to-64-despite-trump-silence-on-crypto">Strategic Bitcoin Reserve Probability Up To 64% Despite Trump Silence On Crypto</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43136512/bitcoin-is-no-threat-to-the-us-dollar-goldman-sachs-ceo-says">Bitcoin Is No &#8216;Threat&#8217; To The US Dollar, Goldman Sachs CEO Says</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43119637/michael-saylors-proposal-to-increase-microstratagys-share-count-approved-by-shareholders-more-bitcoin-purchases-on-the-cards">Michael Saylor&#8217;s Proposal To Increase MicroStratagy&#8217;s Share Count Approved By Shareholders — More Bitcoin Purchases On The Cards?</a></li>
<li><a href="https://www.benzinga.com/top-stories/25/01/43110946/sec-launches-crypto-task-force-to-establish-clear-regulatory-framework">SEC Launches Crypto Task Force To Establish Clear Regulatory Framework</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43119210/bitcoin-miners-helped-texas-avoid-18-billion-energy-costs-report">Bitcoin Miners Helped Texas Avoid $18 Billion Energy Costs: Report</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Worldcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>)</td>
<td>&nbsp;$2.34</td>
<td>+12.7%</td>
</tr>
<tr>
<td>Raydium (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">RAY</a>)</td>
<td>&nbsp;$8.19</td>
<td>+7.1%</td>
</tr>
<tr>
<td>Pudgy Penguins (CRYPTO: PENGU)</td>
<td>&nbsp;$0.02578</td>
<td>+6.4%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Flow Horse emphasized that BlackRock itself hasn&#8217;t purchased Bitcoin; its clients did through the ETF. 
He <a href="https://x.com/TheFlowHorse/status/1882139638568976882">warned</a> that the bullish sentiment could be misleading and noted that spikes in trading volume, including multiples of an ETF&#8217;s average daily volume, often indicate short-term market tops.
Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1882143599141573049">expressed</a> optimism, suggesting a &#8220;Bitcoin god candle&#8221; is imminent, advising traders to focus on the upward potential. 
Technical analyst Kevin described the market as stagnant, with liquidity concentrated between $96,000 and $111,000. 
He highlighted the nearly three months of sideways trading after a brief rally, following eight months of stagnation in late 2024.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Big blocks of liquidity all the way from 96K-111K. That's the current range we're. Beyond that nothing much to update. Market still pretty boring now for close to 3 months. Crazy because we traded sideways for 8 months to end 2024 then we went up for one month and now we have… <a href="https://t.co/jYTMbOCnfd">pic.twitter.com/jYTMbOCnfd</a>
&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1882143081367273650?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
CrediBULL Crypto <a href="https://x.com/CredibleCrypto/status/1882146940500287573">clarified</a> that his high-timeframe BTC chart illustrates market structure rather than precise timing or price levels. 
He identified two key support zones: the current level and $88,000-$95,000.
If these fail, BTC could drop to the mid-$80,000 or even $70,000 range, but the larger bullish structure remains intact as long as the $58,000 higher low holds
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43123173/3-reasons-why-bitcoin-could-hit-122000-soon-10x-research">3 Reasons Why Bitcoin Could Hit $122,000 Soon: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$RAY

$SHIB

$SOL

$WLD

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Reel Downwards, But Trader Hints At 'Bitcoin God Candle Loading'

Hexagon Purus

Comments

Hexagon Purus

Hexagon Purus (HPURF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga